Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $27.67.

Several equities research analysts recently commented on the stock. Wells Fargo & Company began coverage on shares of Kestra Medical Technologies in a research report on Monday. They set an “overweight” rating and a $28.00 target price on the stock. Wolfe Research assumed coverage on shares of Kestra Medical Technologies in a research note on Monday. They issued an “outperform” rating and a $29.00 price objective on the stock. Piper Sandler started coverage on Kestra Medical Technologies in a report on Monday. They set an “overweight” rating and a $27.00 target price on the stock. Stifel Nicolaus began coverage on Kestra Medical Technologies in a research report on Monday. They set a “buy” rating and a $28.00 price objective for the company. Finally, The Goldman Sachs Group initiated coverage on shares of Kestra Medical Technologies in a research report on Monday. They set a “neutral” rating and a $24.00 target price for the company.

Kestra Medical Technologies Price Performance

Shares of NASDAQ KMTS traded up $0.02 during mid-day trading on Monday, hitting $23.45. 44,548 shares of the stock traded hands, compared to its average volume of 290,871. Kestra Medical Technologies has a twelve month low of $20.00 and a twelve month high of $25.98.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.